Manoussa Fanny
YOU?
Author Swipe
View article: 972 Masked T cell engagers designed to drive potent synthetic anti-tumor immunity with favorable tolerability
972 Masked T cell engagers designed to drive potent synthetic anti-tumor immunity with favorable tolerability Open
View article: 1296 Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models
1296 Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity in preclinical models Open
View article: Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S3: Repeated mXTX301 dosing was well tolerated and resulted in dose dependent TGI in mice bearing large (~360mm3) MC38 tumors (a) C57BL/6J mice were implanted subcutaneously with MC38 tumor cells and received a single i…
View article: Supplementary Figure S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S1: A representative triplex fluorescent western blot image showing cleavage of XTX301 in primary human tumor specimens. Antibodies against human IL-12 (Green), human IL-12Rβ2 (Red) and human IgG (Blue) were used, a mer…
View article: Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S3: Repeated mXTX301 dosing was well tolerated and resulted in dose dependent TGI in mice bearing large (~360mm3) MC38 tumors (a) C57BL/6J mice were implanted subcutaneously with MC38 tumor cells and received a single i…
View article: Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S5: IFN-γ production in plasma: MC38 tumor-bearing mice were treated with the indicated doses of mXT301 or unmasked control. Plasma IFN-γ concentration was measured by MSD assay at indicated time points. The data repres…
View article: Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S6: XTX301 induced cell signature and pathway analysis: single-sample Gene Set Enrichment Analysis (ssGSEA) was performed for all samples and for selected gene sets of interest (see figure 5e). Each ssGSEA score summari…
View article: Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S2: XTX301 demonstrates enhanced activity upon proteolytic cleavage in primary cells. (a) Primary mouse splenocytes were pre-activated with PMA & Ionomycin and then incubated with varying doses of rm IL-12 and murine su…
View article: Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S2: pSTAT4 EC50 in HEK-Blue IL-12 RGA and primary CD8 T cells IL-12 HEK-Blue reporter gene cells were incubated with either rh IL-12, unmasked control, or XTX301 at varying doses, and the reporter activity was measured.…
View article: Data from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Data from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
IL12 is a proinflammatory cytokine, that has shown promising antitumor activity in humans by promoting the recruitment and activation of immune cells in tumors. However, the systemic administration of IL12 has been accompanied by considera…
View article: Supplementary Table S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S3: IFN-γ production EC50 in mouse, human, and cynomolgus primary cells The ability of mXTX301 to induce IFN-γ production in mouse splenocytes and XTX301 to induce IFN-γ production in human and cynomolgus monkey PBMCs w…
View article: Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S1: The catalytic efficiency (kcat/Km) of MMP cleavage of XTX301. MMPs from 5 different classes, collagenases (MMP1 and MMP8), gelatinases (MMP2 and MMP9), matrilysin (MMP7), stromelysins (MMP10), and membrane-anchored …
View article: Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S2: pSTAT4 EC50 in HEK-Blue IL-12 RGA and primary CD8 T cells IL-12 HEK-Blue reporter gene cells were incubated with either rh IL-12, unmasked control, or XTX301 at varying doses, and the reporter activity was measured.…
View article: Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S4: Gating strategy for multi-color flow cytometry analysis of tumor-infiltrating and splenic immune cell populations.
View article: Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S5 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S5: IFN-γ production in plasma: MC38 tumor-bearing mice were treated with the indicated doses of mXT301 or unmasked control. Plasma IFN-γ concentration was measured by MSD assay at indicated time points. The data repres…
View article: Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S2: XTX301 demonstrates enhanced activity upon proteolytic cleavage in primary cells. (a) Primary mouse splenocytes were pre-activated with PMA & Ionomycin and then incubated with varying doses of rm IL-12 and murine su…
View article: Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S6 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S6: XTX301 induced cell signature and pathway analysis: single-sample Gene Set Enrichment Analysis (ssGSEA) was performed for all samples and for selected gene sets of interest (see figure 5e). Each ssGSEA score summari…
View article: Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S7: XTX301 caused transient and reversible changes to LFTs and other safety parameters in NHP in a repeat dose GLP toxicology study. Male and female NHPs (N=3/sex; 2/sex for recovery animals) were administered XTX301 by…
View article: Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S7: XTX301 caused transient and reversible changes to LFTs and other safety parameters in NHP in a repeat dose GLP toxicology study. Male and female NHPs (N=3/sex; 2/sex for recovery animals) were administered XTX301 by…
View article: Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S4: Gating strategy for multi-color flow cytometry analysis of tumor-infiltrating and splenic immune cell populations.
View article: Supplementary Table S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S3 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S3: IFN-γ production EC50 in mouse, human, and cynomolgus primary cells The ability of mXTX301 to induce IFN-γ production in mouse splenocytes and XTX301 to induce IFN-γ production in human and cynomolgus monkey PBMCs w…
View article: Supplementary Figure S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S1: A representative triplex fluorescent western blot image showing cleavage of XTX301 in primary human tumor specimens. Antibodies against human IL-12 (Green), human IL-12Rβ2 (Red) and human IgG (Blue) were used, a mer…
View article: Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S1: The catalytic efficiency (kcat/Km) of MMP cleavage of XTX301. MMPs from 5 different classes, collagenases (MMP1 and MMP8), gelatinases (MMP2 and MMP9), matrilysin (MMP7), stromelysins (MMP10), and membrane-anchored …
View article: Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Table S1 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplementary Table S1: The catalytic efficiency (kcat/Km) of MMP cleavage of XTX301. MMPs from 5 different classes, collagenases (MMP1 and MMP8), gelatinases (MMP2 and MMP9), matrilysin (MMP7), stromelysins (MMP10), and membrane-anchored …
View article: Data from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Data from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
IL12 is a proinflammatory cytokine, that has shown promising antitumor activity in humans by promoting the recruitment and activation of immune cells in tumors. However, the systemic administration of IL12 has been accompanied by considera…
View article: Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S4: Gating strategy for multi-color flow cytometry analysis of tumor-infiltrating and splenic immune cell populations.
View article: Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S7 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S7: XTX301 caused transient and reversible changes to LFTs and other safety parameters in NHP in a repeat dose GLP toxicology study. Male and female NHPs (N=3/sex; 2/sex for recovery animals) were administered XTX301 by…
View article: Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S4 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S4: Gating strategy for multi-color flow cytometry analysis of tumor-infiltrating and splenic immune cell populations.
View article: Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S2: XTX301 demonstrates enhanced activity upon proteolytic cleavage in primary cells. (a) Primary mouse splenocytes were pre-activated with PMA & Ionomycin and then incubated with varying doses of rm IL-12 and murine su…
View article: Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies
Supplementary Figure S2 from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies Open
Supplemental Figure S2: XTX301 demonstrates enhanced activity upon proteolytic cleavage in primary cells. (a) Primary mouse splenocytes were pre-activated with PMA & Ionomycin and then incubated with varying doses of rm IL-12 and murine su…